Sellas Life (NASDAQ: SLS) SVP gets 300,000 RSUs vesting through 2029

Q: How do the 300,000 RSUs granted to SLS executive Dragan Cicic vest?

The 300,000 restricted stock units vest as follows: 25% on December 1, 2026 , and 25% on each December 1 thereafter until fully vested, subject to his continued service.

Q: What is Dragan Cicic’s role at SELLAS Life Sciences (SLS)?

Dragan Cicic is reported as an officer of SELLAS Life Sciences Group, Inc., serving as SVP, Chief Development Officer .

Q: Was cash paid for the shares underlying the RSU award to the SLS executive?

The Form 4 lists the transaction price as $0.00 per share , indicating the award reflects equity-based compensation rather than a market purchase.

Q: What type of security is involved in the SLS Form 4 for Dragan Cicic?

The transaction involves Common Stock of SELLAS Life Sciences Group, Inc., delivered through an award of restricted stock units .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. reported an equity award to a senior executive. SVP and Chief Development Officer Dragan Cicic received an award of 300,000 restricted stock units on January 7, 2026. These RSUs are scheduled to vest 25% on December 1, 2026, and 25% on each December 1 thereafter until fully vested, as long as he remains in service with the company on each vesting date. Following this grant, Cicic is shown as beneficially owning 557,805 shares of common stock, held directly. The transaction was reported at a price of $0.00 per share, reflecting the nature of the RSU award rather than a market purchase.

Insider Trade Summary

Net Buyer: 300,000 shares

Net Buy 1 txn

Insider CICIC DRAGAN

Role SVP, Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	300,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 557,805 shares (Direct)

Footnotes (1)

F1. The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/09/2026 - 04:35 PM

FAQ

What insider transaction did SELLAS Life Sciences (SLS) report for Dragan Cicic?

SELLAS Life Sciences reported that SVP and Chief Development Officer Dragan Cicic received an award of 300,000 restricted stock units on January 7, 2026.

How do the 300,000 RSUs granted to SLS executive Dragan Cicic vest?

The 300,000 restricted stock units vest as follows: 25% on December 1, 2026, and 25% on each December 1 thereafter until fully vested, subject to his continued service.

What is Dragan Cicic’s role at SELLAS Life Sciences (SLS)?

Dragan Cicic is reported as an officer of SELLAS Life Sciences Group, Inc., serving as SVP, Chief Development Officer.

How many SELLAS Life Sciences shares does Dragan Cicic beneficially own after this Form 4 transaction?

After the reported RSU award, Dragan Cicic is shown as beneficially owning 557,805 shares of common stock, held directly.

Was cash paid for the shares underlying the RSU award to the SLS executive?

The Form 4 lists the transaction price as $0.00 per share, indicating the award reflects equity-based compensation rather than a market purchase.

What type of security is involved in the SLS Form 4 for Dragan Cicic?

The transaction involves Common Stock of SELLAS Life Sciences Group, Inc., delivered through an award of restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CICIC DRAGAN

(Last)

(First)

(Middle)

C/O SELLAS LIFE SCIENCES GROUP, INC.,

7 TIMES SQUARE, SUITE 2503

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		A		300,000⁽¹⁾	A	$0.00	557,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

	/s/ Daniel Bagliebter, Power of Attorney For: Dragan Cicic	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR